I'm frustrated, but I don't think anything fishy is happening.
The most common outcome over the years for anything NWBO related has been it takes significantly longer than average, but, it gets done.
I assume MHRA decision will be no different. Sometime in late Q4, early Q1, whatever it is, we'll learn that DCVAX-L has been (hopefully) approved, using the artisan method, for the indications originally included in the submission. I think the delay would have been due to a combination of MHRA backlogs, DCVAX-L being a novel therapy, and NWBO taking the absolute longest amount of time possible to answer RFIs.
If the shoe fits.
Market Data 
Markets 
AI
